

--27. (new) The promoter according to claim 26, wherein the PPAR response element has repetition of the same binding site or a combination of different binding sites.

--28. (new) The promoter according to claim 27, wherein the PPAR response element comprises one or more sites having the nucleic acid sequence of SEQ ID NO:1 or a functional variant of SEQ ID NO:1.

--29. (new) The promoter according to claim 26, wherein the PPAR response element comprises the nucleic acid sequence of SEQ ID NOS 1, 2, 3 or 4 or a functional variant of SEQ ID NOS 1, 2, 3 or 4.

A1
Cons
--30. (new) The promoter according to claim 26, wherein said promoter of said PLA2s gene comprises SEQ ID NO:5 or a functional part of SEQ ID NO:5.

--31. (new) The promoter according to claim 26, wherein said functional part of the PLA2s promoter is induced by interleukin-1 β .

--32. (new) The promoter according to claim 30, wherein said functional part of said PLA2s gene comprises at least residues 51 to 61 of SEQ ID NO:5.

--33. (new) The promoter according to claim 30, wherein said functional part of said PLA2s gene comprises at least residues 5 to 170 of SEQ ID NO:5.

--34. (new) The promoter according to claim 30, wherein said functional part of said PLA2s gene comprises at least residues 51 to 170 of SEQ ID NO:5.

--35. (new) The promoter according to claim 26, wherein said PPAR response element is positioned 5' upstream of said functional part of said PLA2s gene.

--36. (new) The promoter according to claim 26, further comprises a gene that confers tissue specificity.

--37. (new) The promoter according to claim 36, wherein said gene confers specificity for the chondrocytic cells.

--38. (new) The promoter according to claim 36, wherein said gene comprises SEQ ID NO:7, a functional part of SEQ ID NO:7 or a variant of SEQ ID NO:7.

--39. (new) A nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NOs 1, 2, 3, 4 or 5 or a functional variant of SEQ ID NOs 1, 2, 3, 4 or 5.

--40. (new) The nucleic acid according to claim 39, further comprising a nucleic acid sequence encoding an anti-inflammatory product.

--41. (new) A vector comprising a nucleic acid sequence encoding said hybrid promoter according to claim 26.

--42. (new) A vector comprising a nucleic acid sequence encoding said nucleic acid according to claim 35.

--43. (new) The vector according to claim 41, wherein said vector is a plasmid.

--44. (new) The vector according to claim 42, wherein said vector is a plasmid.

--45. (new) A composition comprising (i) a nucleic acid according to claim 39 and (ii) a PPAR activator.

--46. (new) A composition comprising (i) a vector according to claim 41 and (ii) a PPAR activator.

--47. (new) A composition comprising (i) a vector according to claim 42 and (ii) a PPAR activator.

--48. (new) A nucleic acid comprising a sequence selected from the class consisting of SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

--49. (new) A nucleic acid comprising the sequence of SEQ ID NO:6.

--50. (new) A cell comprising a hybrid promoter according to claim 26.

--51. (new) A cell comprising a vector according to claim 41.

--52. (new) A cell comprising a vector according to claim 42.--

Please charge the fee of \$18 for the addition of two dependent claims, to the Deposit Account of the undersigned attorneys of record, 25-0120.

REMARKS

The necessary new declaration is submitted herewith.